Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Nutrition - Pharma Stocks in the News: Embark Holdings, GNC, Vitamin Shoppe, Gilead Sciences, Pfizer

GILD, PFE, ZTS
Nutrition - Pharma Stocks in the News: Embark Holdings, GNC, Vitamin Shoppe, Gilead Sciences, Pfizer

CORAL SPRINGS, Florida, June 26, 2013 /PRNewswire/ --

FinancialNewsMedia.com issues market news updates for today's active sports nutrition & pharmaceutical companies:  Embark Holdings, Inc. (OTC: EMBK), GNC Holdings, Inc. (NYSE: GNC), Vitamin Shoppe, Inc. (NYSE:VSI), Gilead Sciences, Inc. (NASDAQ: GILD) and Pfizer Inc. (NYSE: PFE)

Headline News Alert: Embark Holdings, Inc. (OTC: EMBK) subsidiary Muscle Warfare Announces International Distribution Deal out of the United Kingdom. EMBK announced Tuesday that its wholly owned subsidiary Muscle Warfare, Inc. has increased the size of its current distribution deal with its strong and fast growing partner in the United Kingdom. The distribution rights for Muscle Warfare's complete line of elite products granted to UK partner Power Body Nutrition Ltd. has been increased to hit a minimum of 200k in sales for 2013. Muscle Warfare receives very strong support from our UK partner and clear proof of this support was Muscle Warfare being the premier United States based Sports Nutrition Brand, highlighted at their very own and highly popular Power Body Expo. Located in Birmingham, England, the Power Body Expo put the Muscle Warfare brand on strong display from May 17-19th with an incredible looking and centrally located 17 x 33 foot custom made and fully staffed booth to headline their U.S. based distribution partner. Read the full release at http://www.financialnewsmedia.com/stock-investing-business-investing-news/featured-news.php?id=283.

GNC Holdings, Inc. (NYSE: GNC), headquartered in Pittsburgh, PA, is a leading global specialty retailer of health and wellness products, including vitamins, minerals, and herbal supplement products, sports nutrition products and diet products. GNC's sales growth this last quarter was up approximately 6%, with net income per share up an estimated 21%. GNC's cash flow yield is approximately 4.6% with an estimated $1.1 billion in debt. Muscle Warfare, Inc., subsidiary of EMBK, announced recently the launch of its elite sports nutrition brands at select GNC (NYSE: GNC) stores throughout the nation.

Vitamin Shoppe, Inc. (NYSE:VSI) is a leading specialty retailer and direct marketer of nutritional products based in North Bergen, New Jersey. The company sells vitamins, minerals, nutritional supplements, herbs, sports nutrition formulas, homeopathic remedies, green living products, and health and beauty aids to customers located primarily in the United States. VSI carries national brand products as well as exclusive products under the Vitamin Shoppe, BodyTech and True Athlete proprietary brands. Muscle Warfare, Inc products are also distributing product in all 550+ Vitamin Shoppe (NYSE: VSI) stores Nationwide.

Gilead Sciences, Inc. (NASDAQ: GILD) recently announced interim results from a single-arm, open-label Phase 2 study (Study 101-09) evaluating idelalisib (formerly GS-1101), an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin's lymphoma (iNHL) that is refractory (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy. Previously, this has been a largely unstudied population for which there is significant unmet medical need for effective therapy. In the study, single-agent treatment with idelalisib achieved an overall response rate of 53.6 percent, with a median duration of response at this interim analysis of 11.9 months.

Pfizer Inc. (NYSE: PFE) this week announced that, based on preliminary results, its previously announced offer to its shareholders to exchange all, some or none of their shares of Pfizer common stock for shares of Zoetis Inc. (NYSE: ZTS) common stock owned by Pfizer was oversubscribed. The exchange offer expired at 12:00 midnight, New York City time, on June 21, 2013. Under the terms of the exchange offer, 0.9898 shares of Zoetis common stock will be exchanged for each share of Pfizer common stock accepted in the exchange offer.

FinancialNewsMedia.com  is a leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com  for more details. Get an edge on the market with our Premium News Alerts  that are FREE for a limited time at http://www.financialnewsmedia.com/. Follow us on Facebook:  http://www.facebook.com/financialnewsmedia  and Twitter: http://twitter.com/FNMgroup

DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.

FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. FOR FULL DISCLOSURES, PLEASE VISIT http://www.financialnewsmedia.com/disclaimer.php

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company: FN Media Group, LLC
Contact email: editor@financialnewsmedia.com
U.S. Phone: +1(954)345-0611
URL: http://www.financialnewsmedia.com

SOURCE FN Media Group LLC